Because such a strategy has shown benefits in neurodegenerative diseases [46,47], modulating the degradation of CALR mutant proteins by the ERAD-proteasome pathway might represent an appealing strategy to improve the management of CALR-mutated MPN. Here, CALR is linked to myeloproliferative disorder.